Safety and Immunogenicity of Anti–SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants
Top Cited Papers
- 1 September 2021
- journal article
- letter
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (9), 1336-1338
- https://doi.org/10.7326/m21-1341
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant RecipientsJAMA, 2021
- Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virusAmerican Journal of Transplantation, 2021
- Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipientsAmerican Journal of Transplantation, 2021
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature, 2020
- Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort StudyClinical Infectious Diseases, 2020